Infective endocarditis (IE) is a disease caused by microorganisms entering the bloodstream and colonizing damaged heart valves, leading to potentially fatal complications such as congestive heart failure, aneurysm, and stroke (Bashore et al., 2006). Many recent studies suggest that IE incidence is rising (Quan et al., 2020), and mortality rates of 12%-30% are common (Jamil et al., 2019; Ly et al., 2020). Currently, prevention is limited to prophylactic antibiotics before dental procedures (Wilson et al., 2021). The economic burden, potential for side effects, and questionable efficacy Quan et al., 2020;Thornhill et al., 2018) of this practice, as well as the increasing prevalence of antibiotic resistance (Dodds, 2017), suggest the need for new approaches to prevention.In addition, the ability of oral bacteria to enter the bloodstream through any opening in the oral mucosa, which may occur during routine hygiene practices or mastication (Wilson et al., 2007;Wray et al., 2008), explains why prophylaxis given before dental procedures can never prevent all IE. Thus, it would be desirable to identify a drug target that is specific to endocarditis pathogenesis, which